Johnathan Ebben MD, PhD
@JohnEbbenMDPhD
Followers
1K
Following
5K
Media
459
Statuses
3K
Physician-scientist. Aspiring therapeutics developer. Turning basic science into medicine.
Boston, MA
Joined July 2020
#TumorBoardTuesday 😮We had a rare #ASCO25 with several key🗝️updates in #PancreaticCancer So to put this in context: 📢Join us Tuesday, 07-08-25 at 8PM ET as @DrShubhamPant & @DanielHaldarMD 🗣️Optimizing 1L Treatment Selection in mPDAC RT and bring others into the discussion‼️
2
17
57
#TumorBoardTuesday 🧑🎓Did you learn about HIF1 20+y ago❓ 🥸Well now we have agents to target🎯this key pathway👏 📢Join us Tuesday, 06-24-25 at 8PM ET as @Brian_rini & @paulosiqamaral🗣️the use of HIF⛔️in clear cell RCC #kidneycancer RT and bring others into the discussion‼️
1
12
32
#TumorBoardTuesday Did you all recover from #ASCO25 ❓😀 Ready for more learning❓🧑🏫 📢Join us Tuesday, 06-17-25 at 8PM ET as @lungoncdoc & @KelseyPanMD 🗣️Targeting🎯classical EGFR mutations in metastatic #NSCLC RT and bring others into the discussion‼️
4
19
49
#TumorBoardTuesday 📢With all the advances in the Tx of met #breastcancer, how about options for Pts w/ #brainmetastases 🧠 ❓ Join us Tuesday, 03-18-25 at 8 pm ET as @drsarahsam and @IlanaSchlam 🗣️a patient with mBC and🧠metastases RT and bring others into the discussion‼️
2
6
13
20/20 #TumorBoardTuesday Summary Ability to detect oligomets will likely change with more use of PET-PSMA, e.g., patients with biochemical relapse but no apparent mets on conventional CT or bone scan → 74% PSMA-positive lesions
2
4
13
#GI25🎤drop #NEST🪺🙋🏻♂️🙌🏽 |➖➖➖➖➖➖➖➖➖➖ 💯 | | | | | | | | |————————————————— ✅NO RECURRENCES📅! 💡Neoadjuvant immunotherapy keeps delivering! 👉🏽Patients with MSS🧊NOT just MSI-High🔥colorectal #cancer. Goal is to👏🏾*CURE*👏🏾more patients. 🔜Phase2/3 @OncoAlert @ASCO
8
65
151
@JohnEbbenMDPhD @yeung_cynthia @TumorBoardTues @DavidHongMD @DrSarcoma @JCO_ASCO #TumorBoardTuesday 👉This is what @n8pennell taught us years ago in #NSCLC 💵It is much more cost effective just to order a whole🧬panel
0
2
3
@TumorBoardTues @DavidHongMD @DrSarcoma @JCO_ASCO @coloncanada @elena_elez @adasarimd 17/20 #TumorBoardTuesday Clinical trials/ICI in MSS colon cancer, particularly without liver mets showing encouraging ph 1 data: 🔶Rego/nivo/ipi https://t.co/ucADWf3xrz 🔶BOT/BAL https://t.co/AVMNdm5ibB Consider enrolling in clinical trial if available @CDNCancerTrials
nature.com
Nature Medicine - In an ongoing phase 1 trial, the combination of two new immunotherapies targeting CTLA-4 and PD-1 was overall well tolerated and elicited encouraging clinical responses in...
3
3
7
Great pleasure to re-introduce @DAielloMD to #lcsm in new role tonite- previous @TumorBoardTues ctDNA session champion- @MontefioreNYC resident➡️fellow➡️chief fellow➡️now brand new @EinsteinMed med onc faculty! She also just had a baby a few months ago BUT i am told thoracic onc
#TumorBoardTuesday In this holiday season, I am so ready to spend an hour smiling😀laughing😆and learning🧑🏼🎓for our next session 📢Join us Tuesday, 12-10-24 at 8PM ET as @BalazsHalmosMD & @DAielloMD🗣️periOp mgmt of resectable #NSCLC RT and bring others into the discussion‼️
0
2
15
@TumorBoardTues @BalazsHalmosMD @IntegrityCE @DrRoyHerbstYale @NEJM 5/29 #TumorBoardTuesday 👩🏫Mini tweetorial 4 👨🏫 👉PACIFIC regimen = SOC for Stage IIIB NSCLC 🧐No OS benefit for EGFRm subset.. 💁♀️LAURA ⭐️Phase III - osi after chemoRT ⭐️Unresectable stage III EGFRm NSCLC 👏Osi vs placebo➡️med PFS 39.1 vs 5.6 mo 🏆Osi after chemoRT = new SOC
2
6
12
@TumorBoardTues @BalazsHalmosMD @IntegrityCE @DrRoyHerbstYale @NEJM 3/29 #TumorBoardTuesday 👩🏫Mini tweetorial 2👨🏫 🚨ADAURA Results 💊Adjuvant osimertinib vs placebo ⭐️5 yr OS 88% vs 78% (HR 0.49, p <0.001) ⭐️DFS 65.8 mo vs 28.1 mo 🏆Adj osimertinib is now FDA approved/SOC
2
3
5
#TumorBoardTuesday In this holiday season, I am so ready to spend an hour smiling😀laughing😆and learning🧑🏼🎓for our next session 📢Join us Tuesday, 12-10-24 at 8PM ET as @BalazsHalmosMD & @DAielloMD🗣️periOp mgmt of resectable #NSCLC RT and bring others into the discussion‼️
4
8
24
Thoracic @TumorBoardTues during Lung Cancer Awareness Month? An easy YES!! Join @KelseyPanMD & I this week as we discuss the ever-evolving 1L treatment landscape of metastatic EGFR+ NSCLC! 📅 11/12/24 ⏰ 8-9 PM ET #lcsm #lcam #lungcancerawarenessmonth
4
15
53
What is the role of HER2 directed therapy in #HER2+ #urothelialcancer? Not something I think of right away- but with the approval of T-DXd for IHC 3+ in ANY site, how do we think about this? Join in w #TumorBoardTuesday live! 👇
@TumorBoardTues @MattGalsky 1/27 #TumorBoardTuesday #OncTwitter Your patient presents for follow up: 68 year old 👨 with no significant PMH except urothelial cancer 📖 Previously treated with cystectomy ➡️ adjuvant gem/cis ‼️ Metastatic nodal recurrence detected via ctDNA and PET after 6 months
1
0
5
@TumorBoardTues @MattGalsky 1/27 #TumorBoardTuesday #OncTwitter Your patient presents for follow up: 68 year old 👨 with no significant PMH except urothelial cancer 📖 Previously treated with cystectomy ➡️ adjuvant gem/cis ‼️ Metastatic nodal recurrence detected via ctDNA and PET after 6 months
2
5
12
#TumorBoardTuesday 👏It is amazing how many HER2🎯💊options there are for metastatic bladder cancer 📢Join us Tuesday, 10-29-24 at 8PM ET as @MattGalsky & @ericjmiller7 🗣️the multitude of therapies for HER2+ Bladder Cancer RT and bring others into the discussion‼️
3
10
24
@TumorBoardTues @curijoey 12/20 #TumorBoardTuesday 👩🏻🏫Mini tweetorial 6👨🏻🏫 📌What is HER2 ultralow? 🔹 Faint, incomplete staining in ≤10% tumor cells 🔹 20-25% of HR+/HER2- mBC are HER2 ultralow 🚨 repeat biopsy to broaden eligibility to TDXd
3
3
5
@TumorBoardTues @CentralParkWMD @JCO_ASCO @JonathanOstrem @kevansf @RonaYaeger @NEJM @GIcancerDoc @NatureMedicine 16/24 Early P1 data from RMC-6236, a RAS-on inhibitor targeting multiple mutant alleles, shows response signal across KRAS variants in patients who have received multiple prior lines of treatment 🤩 📰P3 RCT vs chemo is coming! https://t.co/4nHGEkblNh
2
4
7
More on this from the Sabin Vaccine Institute, a non-profit working on developing vaccines for high-consequence diseases in low- and middle-income countries. Truly a mind-blowing achievement and an exemplar for future outbreak response.
In response to a request from the government of Rwanda and @RwandaHealth to support its ongoing #marburg outbreak response, we have provided an initial shipment of ~700 investigational Marburg vaccine doses to be used in a trial targeting frontline workers. We dispatched the
2
10
109
@TumorBoardTues @GABOUALFA @IntegrityCE @MSKCancerCenter @MSK_DeptOfMed 16/24 Five-year analysis of HIMALAYA 📢Sustained OS benefit with STRIDE vs sorafenib 📢5-year OS rates 19.6% with STRIDE vs 9.4% with sorafenib @GABOUALFA
3
5
8